Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Коррекция нарушений микробного состава кишечника как потенциальное звено в комплексной терапии пациентов с COVID-19 - Журнал Терапевтический архив №2 Вопросы гастроэнтерологии 2022
Коррекция нарушений микробного состава кишечника как потенциальное звено в комплексной терапии пациентов с COVID-19
Ахмедов В.А. Коррекция нарушений микробного состава кишечника как потенциальное звено в комплексной терапии пациентов с COVID-19. Терапевтический архив. 2022;94(2):277–282.
DOI: 10.26442/00403660.2022.02.201388
DOI: 10.26442/00403660.2022.02.201388
DOI: 10.26442/00403660.2022.02.201388
________________________________________________
DOI: 10.26442/00403660.2022.02.201388
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье отражены потенциальные возможности коррекции нарушений микробиоты кишечника в комплексной терапии пациентов с COVID-19. Отмечено, что включение в рацион питания пищевых волокон способствует защите от нарушения целостности кишечного барьера и может ограничивать бактериальную транслокацию в системный кровоток. Отражена возможность применения псиллиума (Мукофальк), действие которого реализуется как через его сорбционные, цитопротективные и противовоспалительные свойства при вирусном поражении желудочно-кишечного тракта, так и через стимуляцию собственной полезной микробиоты кишечника. Представлены исследования перспектив применения пробиотиков, синбиотиков в комплексной терапии пациентов с COVID-19. Приведены подробные данные о механизмах положительного влияния препаратов короткоцепочечных жирных кислот на снижение тяжести заболевания у пациентов с COVID-19. Отмечено, что прием препарата Закофальк® приводит к существенному росту собственной бутират-продуцирующей микробиоты (Faecalibacterium prausnitzii) и подавлению роста условно-патогенной флоры с провоспалительной активностью. Приведены результаты недавнего исследования, показавшие, что у пациентов с легким течением COVID-инфекции с наличием респираторных и интестинальных симптомов назначение Закофалька в течение 30 дней (3 таблетки в день) приводило к достоверно более быстрой нормализации стула (к 7-му дню), стойкой нормализация частоты и консистенции стула к 21-му дню и достоверно более выраженному регрессу вздутия и боли в животе, а также снижению риска развития постинфекционного синдрома раздраженного кишечника.
Ключевые слова: COVID-19, кишечная микробиота, пробиотики, бутират, пищевые волокна, псиллиум
Keywords: COVID-19, gut microbiota, probiotics, butyrate, dietary fiber, psyllium
Ключевые слова: COVID-19, кишечная микробиота, пробиотики, бутират, пищевые волокна, псиллиум
________________________________________________
Keywords: COVID-19, gut microbiota, probiotics, butyrate, dietary fiber, psyllium
Полный текст
Список литературы
1. Baig AM. Computing the effects of SARS-CoV-2 on respiration regulatory mechanisms in COVID-19. ACS Chem Neurosci. 2020;11:2416-21. DOI:10.1021/acschemneuro.0c00349
2. Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. DOI:10.3389/fimmu.2020.01446
3. Camilleri M, Lyle BJ, Madsen KL, et al. Role for diet in normal gut barrier function: developing guidance within the framework of food-labeling regulations. Am J Physiol Gastrointest Liver Physiol. 2019;317:G17-39. DOI:10.1152/ajpgi.00063.2019
4. Conte L, Toraldo DM. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170. DOI:10.1177/1753466620937170
5. Полевая Е.В., Вахитов Т.Я., Ситкин С.И. Энтеросорбционные свойства псиллиума (Мукофалька®) и возможные механизмы его действия при кишечных инфекциях. Клинические перспективы гастроэнтерологии, гепатологии. 2011;2:35-9 [Polevaya YeV, Vakhitov TYa, Sitkin SI. Enterosorbtion properties of psyllium (Mucofalk®) and its probable mechanisms at intestinal infections. Klinicheskie perspektivy gastroenterologii, gepatologii. 2011;2:35-9 (in Russian)].
6. Ардатская М.Д., Буторова Л.И., Калашникова М.А., и др. Гастроэнтерологические симптомы у пациентов с COVID-19 легкой тяжести: возможности оптимизации антидиарейной терапии. Терапевтический архив. 2021;93(8):923-31 [Ardatskaya MD, Butorova LI, Kalashnikova MA, et al. Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(8):923-31 (in Russian)].
DOI:10.26442/00403660.2021.08.201020
7. Тихонова Е.П., Кузьмина Т.Ю., Миноранская Е.И., Миноранская Н.С. Опыт применения Мукофалька® в лечении сальмонеллеза. Клинические перспективы гастроэнтерологии, гепатологии. 2011;4:36-9 [Tikhonova YeP, Kuzmina TYu, Minoranskaya YeI, Minoranskaya NS. The practical issues of application of Mucofalk® in Salmonella infection. Klinicheskie perspektivy gastroenterologii, gepatologii. 2011;4:36-9 (in Russian)].
8. Iddir M, Brito A, Dingeo G, et al. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. Nutrients. 2020;12(6):1562. DOI:10.3390/nu12061562
9. Trompette A, Gollwitzer ES, Pattaroni C, et al. Dietary Fiber Confers Protection against Flu by Shaping Ly6c(-) Patrolling Monocyte Hematopoiesis and CD8(+) T Cell Metabolism. Immunity. 2018;48:992-1005. DOI:10.1016/j.immuni.2018.04.022
10. Alameddine J, Godefroy E, Papargyris L, et al. Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. Front Immunol. 2019;10:143. DOI:10.3389/fimmu.2019.00143
11. Zuo T, Liu Q, Zhang F, et al. Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Microbiome. 2021;9(1):91.
DOI:10.1186/s40168-021-01008-x
12. Benus RF, van der Werf TS, Welling GW, et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr. 2010;104:693-700. DOI:10.1017/S0007114510001030
13. Barbieri N, Herrera M, Salva S, et al. Lactobacillus rhamnosus CRL1505 nasal administration improves recovery of T-cell mediated immunity against pneumococcal infection in malnourished mice. Benef Microbes. 2017;8:393-405. DOI:10.3920/BM2016.0152
14. Laursen RP, Hojsak I. Probiotics for respiratory tract infections in children attending day care centers a systematic review. Eur J Pediatr. 2018;177:979-94.
DOI:10.1007/s00431-018-3167-1
15. Xia Y, Cao J, Wang M, et al. Effects of Lactococcus lactis subsp. lactis JCM5805 on colonization dynamics of gut microbiota and regulation of immunity in early ontogenetic stages of tilapia. Fish Shellfish Immunol. 2019;86:53-63. DOI:10.1016/j.fsi.2018.11.022
16. Yasui H, Kiyoshima J, Hori T, et al. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol. 1999;6:186-92. DOI:10.1128/CDLI.6.2.186-192.1999
17. Su M, Jia Y, Li Y, et al. Probiotics for the prevention of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. Respir Care. 2020;65:673-85. DOI:10.4187/respcare.07097
18. Zhang Q, Yue S, Wang W, et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Am J Chin Med. 2021;49(4):785-803. DOI:10.1142/S0192415X21500373
19. Han SK, Shin YJ, Lee DY, et al. Lactobacillus rhamnosus HDB1258 modulates gut microbiota-mediated immune response in mice with or without lipopolysaccharide-induced systemic inflammation. BMC Microbiol. 2021;21:146. DOI:10.1186/s12866-021-02192-4
20. Al Kassaa I, Hober D, Hamze M, et al. Antiviral potential of lactic acid bacteria and their bacteriocins. Probiotics Antimicrob Proteins. 2014;6:177-85. DOI:10.1007/s12602-014-9162-6
21. Baindara P, Chakraborty R, Holliday ZM, et al. Oral probiotics in coronavirus disease 2019: Connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials. New Microbes New Infect. 2021;40:100837.
22. Starosila D, Rybalko S, Varbanetz L, et al. Anti-influenza activity of a Bacillus subtilis probiotic strain. Antimicrob Agents Chemother. 2017;61:e00539-17. DOI:10.1128/AAC.00539-17
23. Zeng J, Wang CT, Zhang FS, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: A randomized controlled multicenter trial. Intensive Care Med. 2016;42:1018-28. DOI:10.1007/s00134-016-4303-x
24. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: A blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182:1058-64. DOI:10.1164/rccm.200912-1853OC
25. Jung YJ, Lee YT, Ngo VL, et al. Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection. Sci Rep. 2017;7:17360. DOI:10.1038/s41598-017-17487-8
26. Bidossi A, De Grandi R, Toscano M, et al. Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract. BMC Infect Dis. 2018;18:653. DOI:10.1186/s12879-018-3576-9
27. Di Pierro F. A possible probiotic (S. salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2. Minerva Med. 2020;111:281-3. DOI:10.23736/S0026-4806.20.06570-2
28. Bottari B, Castellone V, Neviani E. Probiotics and COVID-19. Int J Food Sci Nutr. 2021;72:293-9. DOI:10.1080/09637486.2020.1807475
29. Kumar R, Seo BJ, Mun MR, et al. Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens. Trop Anim Health Prod. 2010;42:1855-60. DOI:10.1007/s11250-010-9648-5
30. Chai W, Burwinkel M, Wang Z, et al. Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol. 2013;158:799-807.
DOI:10.1007/s00705-012-1543-0
31. Liu YS, Liu Q, Jiang YL, et al. Surface-displayed porcine IFN-lambda3 in Lactobacillus plantarum inhibits porcine enteric coronavirus infection of porcine intestinal epithelial cells. J Microbiol Biotechnol. 2020;30:515-25. DOI:10.4014/jmb.1909.09041
32. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. 2020;5(7):644-5. DOI:10.1016/S2468-1253(20)30122-9
33. Esaiassen E, Cavanagh P, Hjerde E, et al. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis. 2016;22:1664-6. DOI:10.3201/eid2209.160033
34. Alataby H, Atemnkeng F, Bains SS, et al. A COVID-19 case complicated by Candida dubliniensis and Klebsiella pneumoniae-carbapenem-resistant Enterobacteriaceae. J Med Cases. 2020;1:403-6. DOI:10.14740/jmc3588
35. Ceccarelli G, Borrazzo C, Pinacchio C, et al. Oral bacteriotherapy in patients with COVID-19: A retrospective cohort study. Front Nutr. 2020;7:613928. DOI:10.3389/fnut.2020.613928
36. d’Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the management of SARS-CoV2 Infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med. 2020;7:389. DOI:10.3389/fmed.2020.00389
37. Son SJ, Koh JH, Park MR, et al. Effect of the Lactobacillus rhamnosus strain GG and tagatose as a synbiotic combination in a dextran sulfate sodium-induced colitis murine model. J Dairy Sci. 2019;102:2844-53. DOI:10.3168/jds.2018-15013
38. Fuhren J, Schwalbe M, Rösch C, et al. Dietary inulin increases Lactiplantibacillus plantarum strain Lp900 persistence in rats depending on the dietary-calcium level. Appl Environ Microbiol. 2021;87:e00122-21. DOI:10.1128/AEM.00122-21
39. Shinde T, Vemuri R, Shastri S, et al. Modulating the Microbiome and Immune Responses Using Whole Plant Fibre in Synbiotic Combination with Fibre-Digesting Probiotic Attenuates Chronic Colonic Inflammation in Spontaneous Colitic Mice Model of IBD. Nutrients. 2020;12:2380. DOI:10.3390/nu12082380
40. Stadlbauer V, Horvath A, Komarova I, et al. Dysbiosis in early sepsis can be modulated by a multispecies probiotic: A randomised controlled pilot trial. Benef Microbes. 2019;10:265-78. DOI:10.3920/BM2018.0067
41. Moser AM, Spindelboeck W, Halwachs B, et al. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome. Eur J Nutr. 2019;58:2767-78. DOI:10.1007/s00394-018-1826-7
42. Chen J, Vitetta LJ. Modulation of Gut Microbiota for the Prevention and Treatment of COVID-19. Clin Med. 2021;10(13):2903. DOI:10.3390/jcm10132903
43. Archer DL, Kramer DC. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection. Front Med. 2020;7:292. DOI:10.3389/fmed.2020.00292
44. Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8:351-8. DOI:10.1080/19490976.2017.1284732
45. Chen J, Hall S, Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021;31(5):1-13. DOI:10.1002/rmv.2211
46. Luu M, Weigand K, Wedi F, et al. Regulation of the effector function of CD8(+) T cells by gut microbiota-derived metabolite butyrate. Sci Rep. 2018;8:14430. DOI:10.1002/rmv.2211
47. Takahashi Y, Hayakawa A, Sano R, et al. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19. Sci Rep. 2021;11:3379. DOI:10.1038/s41598-021-82970-2
48. Chemudupati M, Kenney AD, Smith AC, et al. Butyrate Reprograms Expression of Specific Interferon-Stimulated Genes. J Virol. 2020;94(16):e00326-20. DOI:10.1128/JVI.00326-20
49. Гриневич В.Б., Кравчук Ю.А., Педь В.И., и др. Ведение пациентов с заболеваниями органов пищеварения в период пандемии COVID-19. Клинические рекомендации Научного общества гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2020;179(7):4-51 [Grinevich VB, Kravchuk YuA, Ped VI, et al. Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2020;179(7):4-51 (in Russian)]. DOI:10.31146/1682-8658-ecg-179-7-4-51
50. Бахарев С.Д., Бауло Е.В., Быкова С.В., и др. COVID-19 и тонкая кишка. Терапевтический архив. 2021;93(3):343-7 [Bakharev SD, Baulo EV, Bykova SV, et al. COVID-19 and the small intestine. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(3):343-7 (in Russian)]. DOI:10.26442/00403660.2021.03.20066
2. Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. DOI:10.3389/fimmu.2020.01446
3. Camilleri M, Lyle BJ, Madsen KL, et al. Role for diet in normal gut barrier function: developing guidance within the framework of food-labeling regulations. Am J Physiol Gastrointest Liver Physiol. 2019;317:G17-39. DOI:10.1152/ajpgi.00063.2019
4. Conte L, Toraldo DM. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170. DOI:10.1177/1753466620937170
5. Polevaya YeV, Vakhitov TYa, Sitkin SI. Enterosorbtion properties of psyllium (Mucofalk®) and its probable mechanisms at intestinal infections. Klinicheskie perspektivy gastroenterologii, gepatologii. 2011;2:35-9 (in Russian).
6. Ardatskaya MD, Butorova LI, Kalashnikova MA, et al. Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(8):923-31 (in Russian). DOI:10.26442/00403660.2021.08.201020
7. Tikhonova YeP, Kuzmina TYu, Minoranskaya YeI, Minoranskaya NS. The practical issues of application of Mucofalk® in Salmonella infection. Klinicheskie perspektivy gastroenterologii, gepatologii. 2011;4:36-9 (in Russian).
8. Iddir M, Brito A, Dingeo G, et al. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. Nutrients. 2020;12(6):1562. DOI:10.3390/nu12061562
9. Trompette A, Gollwitzer ES, Pattaroni C, et al. Dietary Fiber Confers Protection against Flu by Shaping Ly6c(-) Patrolling Monocyte Hematopoiesis and CD8(+) T Cell Metabolism. Immunity. 2018;48:992-1005. DOI:10.1016/j.immuni.2018.04.022
10. Alameddine J, Godefroy E, Papargyris L, et al. Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. Front Immunol. 2019;10:143. DOI:10.3389/fimmu.2019.00143
11. Zuo T, Liu Q, Zhang F, et al. Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Microbiome. 2021;9(1):91.
DOI:10.1186/s40168-021-01008-x
12. Benus RF, van der Werf TS, Welling GW, et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr. 2010;104:693-700. DOI:10.1017/S0007114510001030
13. Barbieri N, Herrera M, Salva S, et al. Lactobacillus rhamnosus CRL1505 nasal administration improves recovery of T-cell mediated immunity against pneumococcal infection in malnourished mice. Benef Microbes. 2017;8:393-405. DOI:10.3920/BM2016.0152
14. Laursen RP, Hojsak I. Probiotics for respiratory tract infections in children attending day care centers a systematic review. Eur J Pediatr. 2018;177:979-94.
DOI:10.1007/s00431-018-3167-1
15. Xia Y, Cao J, Wang M, et al. Effects of Lactococcus lactis subsp. lactis JCM5805 on colonization dynamics of gut microbiota and regulation of immunity in early ontogenetic stages of tilapia. Fish Shellfish Immunol. 2019;86:53-63. DOI:10.1016/j.fsi.2018.11.022
16. Yasui H, Kiyoshima J, Hori T, et al. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol. 1999;6:186-92. DOI:10.1128/CDLI.6.2.186-192.1999
17. Su M, Jia Y, Li Y, et al. Probiotics for the prevention of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. Respir Care. 2020;65:673-85. DOI:10.4187/respcare.07097
18. Zhang Q, Yue S, Wang W, et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Am J Chin Med. 2021;49(4):785-803. DOI:10.1142/S0192415X21500373
19. Han SK, Shin YJ, Lee DY, et al. Lactobacillus rhamnosus HDB1258 modulates gut microbiota-mediated immune response in mice with or without lipopolysaccharide-induced systemic inflammation. BMC Microbiol. 2021;21:146. DOI:10.1186/s12866-021-02192-4
20. Al Kassaa I, Hober D, Hamze M, et al. Antiviral potential of lactic acid bacteria and their bacteriocins. Probiotics Antimicrob Proteins. 2014;6:177-85. DOI:10.1007/s12602-014-9162-6
21. Baindara P, Chakraborty R, Holliday ZM, et al. Oral probiotics in coronavirus disease 2019: Connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials. New Microbes New Infect. 2021;40:100837.
22. Starosila D, Rybalko S, Varbanetz L, et al. Anti-influenza activity of a Bacillus subtilis probiotic strain. Antimicrob Agents Chemother. 2017;61:e00539-17. DOI:10.1128/AAC.00539-17
23. Zeng J, Wang CT, Zhang FS, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: A randomized controlled multicenter trial. Intensive Care Med. 2016;42:1018-28. DOI:10.1007/s00134-016-4303-x
24. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: A blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182:1058-64. DOI:10.1164/rccm.200912-1853OC
25. Jung YJ, Lee YT, Ngo VL, et al. Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection. Sci Rep. 2017;7:17360. DOI:10.1038/s41598-017-17487-8
26. Bidossi A, De Grandi R, Toscano M, et al. Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract. BMC Infect Dis. 2018;18:653. DOI:10.1186/s12879-018-3576-9
27. Di Pierro F. A possible probiotic (S. salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2. Minerva Med. 2020;111:281-3. DOI:10.23736/S0026-4806.20.06570-2
28. Bottari B, Castellone V, Neviani E. Probiotics and COVID-19. Int J Food Sci Nutr. 2021;72:293-9. DOI:10.1080/09637486.2020.1807475
29. Kumar R, Seo BJ, Mun MR, et al. Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens. Trop Anim Health Prod. 2010;42:1855-60. DOI:10.1007/s11250-010-9648-5
30. Chai W, Burwinkel M, Wang Z, et al. Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol. 2013;158:799-807. DOI:10.1007/s00705-012-1543-0
31. Liu YS, Liu Q, Jiang YL, et al. Surface-displayed porcine IFN-lambda3 in Lactobacillus plantarum inhibits porcine enteric coronavirus infection of porcine intestinal epithelial cells. J Microbiol Biotechnol. 2020;30:515-25. DOI:10.4014/jmb.1909.09041
32. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. 2020;5(7):644-5. DOI:10.1016/S2468-1253(20)30122-9
33. Esaiassen E, Cavanagh P, Hjerde E, et al. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis. 2016;22:1664-6. DOI:10.3201/eid2209.160033
34. Alataby H, Atemnkeng F, Bains SS, et al. A COVID-19 case complicated by Candida dubliniensis and Klebsiella pneumoniae-carbapenem-resistant Enterobacteriaceae. J Med Cases. 2020;1:403-6. DOI:10.14740/jmc3588
35. Ceccarelli G, Borrazzo C, Pinacchio C, et al. Oral bacteriotherapy in patients with COVID-19: A retrospective cohort study. Front Nutr. 2020;7:613928. DOI:10.3389/fnut.2020.613928
36. d’Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the management of SARS-CoV2 Infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med. 2020;7:389. DOI:10.3389/fmed.2020.00389
37. Son SJ, Koh JH, Park MR, et al. Effect of the Lactobacillus rhamnosus strain GG and tagatose as a synbiotic combination in a dextran sulfate sodium-induced colitis murine model. J Dairy Sci. 2019;102:2844-53. DOI:10.3168/jds.2018-15013
38. Fuhren J, Schwalbe M, Rösch C, et al. Dietary inulin increases Lactiplantibacillus plantarum strain Lp900 persistence in rats depending on the dietary-calcium level. Appl Environ Microbiol. 2021;87:e00122-21. DOI:10.1128/AEM.00122-21
39. Shinde T, Vemuri R, Shastri S, et al. Modulating the Microbiome and Immune Responses Using Whole Plant Fibre in Synbiotic Combination with Fibre-Digesting Probiotic Attenuates Chronic Colonic Inflammation in Spontaneous Colitic Mice Model of IBD. Nutrients. 2020;12:2380. DOI:10.3390/nu12082380
40. Stadlbauer V, Horvath A, Komarova I, et al. Dysbiosis in early sepsis can be modulated by a multispecies probiotic: A randomised controlled pilot trial. Benef Microbes. 2019;10:265-78. DOI:10.3920/BM2018.0067
41. Moser AM, Spindelboeck W, Halwachs B, et al. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome. Eur J Nutr. 2019;58:2767-78. DOI:10.1007/s00394-018-1826-7
42. Chen J, Vitetta LJ. Modulation of Gut Microbiota for the Prevention and Treatment of COVID-19. Clin Med. 2021;10(13):2903. DOI:10.3390/jcm10132903
43. Archer DL, Kramer DC. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection. Front Med. 2020;7:292. DOI:10.3389/fmed.2020.00292
44. Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8:351-8. DOI:10.1080/19490976.2017.1284732
45. Chen J, Hall S, Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021;31(5):1-13. DOI:10.1002/rmv.2211
46. Luu M, Weigand K, Wedi F, et al. Regulation of the effector function of CD8(+) T cells by gut microbiota-derived metabolite butyrate. Sci Rep. 2018;8:14430. DOI:10.1002/rmv.2211
47. Takahashi Y, Hayakawa A, Sano R, et al. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19. Sci Rep. 2021;11:3379. DOI:10.1038/s41598-021-82970-2
48. Chemudupati M, Kenney AD, Smith AC, et al. Butyrate Reprograms Expression of Specific Interferon-Stimulated Genes. J Virol. 2020;94(16):e00326-20. DOI:10.1128/JVI.00326-20
49. Grinevich VB, Kravchuk YuA, Ped VI, et al. Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2020;179(7):4-51 (in Russian). DOI:10.31146/1682-8658-ecg-179-7-4-51
50. Bakharev SD, Baulo EV, Bykova SV, et al. COVID-19 and the small intestine. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(3):343-7 (in Russian). DOI:10.26442/00403660.2021.03.20066
2. Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. DOI:10.3389/fimmu.2020.01446
3. Camilleri M, Lyle BJ, Madsen KL, et al. Role for diet in normal gut barrier function: developing guidance within the framework of food-labeling regulations. Am J Physiol Gastrointest Liver Physiol. 2019;317:G17-39. DOI:10.1152/ajpgi.00063.2019
4. Conte L, Toraldo DM. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170. DOI:10.1177/1753466620937170
5. Полевая Е.В., Вахитов Т.Я., Ситкин С.И. Энтеросорбционные свойства псиллиума (Мукофалька®) и возможные механизмы его действия при кишечных инфекциях. Клинические перспективы гастроэнтерологии, гепатологии. 2011;2:35-9 [Polevaya YeV, Vakhitov TYa, Sitkin SI. Enterosorbtion properties of psyllium (Mucofalk®) and its probable mechanisms at intestinal infections. Klinicheskie perspektivy gastroenterologii, gepatologii. 2011;2:35-9 (in Russian)].
6. Ардатская М.Д., Буторова Л.И., Калашникова М.А., и др. Гастроэнтерологические симптомы у пациентов с COVID-19 легкой тяжести: возможности оптимизации антидиарейной терапии. Терапевтический архив. 2021;93(8):923-31 [Ardatskaya MD, Butorova LI, Kalashnikova MA, et al. Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(8):923-31 (in Russian)].
DOI:10.26442/00403660.2021.08.201020
7. Тихонова Е.П., Кузьмина Т.Ю., Миноранская Е.И., Миноранская Н.С. Опыт применения Мукофалька® в лечении сальмонеллеза. Клинические перспективы гастроэнтерологии, гепатологии. 2011;4:36-9 [Tikhonova YeP, Kuzmina TYu, Minoranskaya YeI, Minoranskaya NS. The practical issues of application of Mucofalk® in Salmonella infection. Klinicheskie perspektivy gastroenterologii, gepatologii. 2011;4:36-9 (in Russian)].
8. Iddir M, Brito A, Dingeo G, et al. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. Nutrients. 2020;12(6):1562. DOI:10.3390/nu12061562
9. Trompette A, Gollwitzer ES, Pattaroni C, et al. Dietary Fiber Confers Protection against Flu by Shaping Ly6c(-) Patrolling Monocyte Hematopoiesis and CD8(+) T Cell Metabolism. Immunity. 2018;48:992-1005. DOI:10.1016/j.immuni.2018.04.022
10. Alameddine J, Godefroy E, Papargyris L, et al. Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. Front Immunol. 2019;10:143. DOI:10.3389/fimmu.2019.00143
11. Zuo T, Liu Q, Zhang F, et al. Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Microbiome. 2021;9(1):91.
DOI:10.1186/s40168-021-01008-x
12. Benus RF, van der Werf TS, Welling GW, et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr. 2010;104:693-700. DOI:10.1017/S0007114510001030
13. Barbieri N, Herrera M, Salva S, et al. Lactobacillus rhamnosus CRL1505 nasal administration improves recovery of T-cell mediated immunity against pneumococcal infection in malnourished mice. Benef Microbes. 2017;8:393-405. DOI:10.3920/BM2016.0152
14. Laursen RP, Hojsak I. Probiotics for respiratory tract infections in children attending day care centers a systematic review. Eur J Pediatr. 2018;177:979-94.
DOI:10.1007/s00431-018-3167-1
15. Xia Y, Cao J, Wang M, et al. Effects of Lactococcus lactis subsp. lactis JCM5805 on colonization dynamics of gut microbiota and regulation of immunity in early ontogenetic stages of tilapia. Fish Shellfish Immunol. 2019;86:53-63. DOI:10.1016/j.fsi.2018.11.022
16. Yasui H, Kiyoshima J, Hori T, et al. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol. 1999;6:186-92. DOI:10.1128/CDLI.6.2.186-192.1999
17. Su M, Jia Y, Li Y, et al. Probiotics for the prevention of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. Respir Care. 2020;65:673-85. DOI:10.4187/respcare.07097
18. Zhang Q, Yue S, Wang W, et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Am J Chin Med. 2021;49(4):785-803. DOI:10.1142/S0192415X21500373
19. Han SK, Shin YJ, Lee DY, et al. Lactobacillus rhamnosus HDB1258 modulates gut microbiota-mediated immune response in mice with or without lipopolysaccharide-induced systemic inflammation. BMC Microbiol. 2021;21:146. DOI:10.1186/s12866-021-02192-4
20. Al Kassaa I, Hober D, Hamze M, et al. Antiviral potential of lactic acid bacteria and their bacteriocins. Probiotics Antimicrob Proteins. 2014;6:177-85. DOI:10.1007/s12602-014-9162-6
21. Baindara P, Chakraborty R, Holliday ZM, et al. Oral probiotics in coronavirus disease 2019: Connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials. New Microbes New Infect. 2021;40:100837.
22. Starosila D, Rybalko S, Varbanetz L, et al. Anti-influenza activity of a Bacillus subtilis probiotic strain. Antimicrob Agents Chemother. 2017;61:e00539-17. DOI:10.1128/AAC.00539-17
23. Zeng J, Wang CT, Zhang FS, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: A randomized controlled multicenter trial. Intensive Care Med. 2016;42:1018-28. DOI:10.1007/s00134-016-4303-x
24. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: A blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182:1058-64. DOI:10.1164/rccm.200912-1853OC
25. Jung YJ, Lee YT, Ngo VL, et al. Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection. Sci Rep. 2017;7:17360. DOI:10.1038/s41598-017-17487-8
26. Bidossi A, De Grandi R, Toscano M, et al. Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract. BMC Infect Dis. 2018;18:653. DOI:10.1186/s12879-018-3576-9
27. Di Pierro F. A possible probiotic (S. salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2. Minerva Med. 2020;111:281-3. DOI:10.23736/S0026-4806.20.06570-2
28. Bottari B, Castellone V, Neviani E. Probiotics and COVID-19. Int J Food Sci Nutr. 2021;72:293-9. DOI:10.1080/09637486.2020.1807475
29. Kumar R, Seo BJ, Mun MR, et al. Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens. Trop Anim Health Prod. 2010;42:1855-60. DOI:10.1007/s11250-010-9648-5
30. Chai W, Burwinkel M, Wang Z, et al. Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol. 2013;158:799-807.
DOI:10.1007/s00705-012-1543-0
31. Liu YS, Liu Q, Jiang YL, et al. Surface-displayed porcine IFN-lambda3 in Lactobacillus plantarum inhibits porcine enteric coronavirus infection of porcine intestinal epithelial cells. J Microbiol Biotechnol. 2020;30:515-25. DOI:10.4014/jmb.1909.09041
32. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. 2020;5(7):644-5. DOI:10.1016/S2468-1253(20)30122-9
33. Esaiassen E, Cavanagh P, Hjerde E, et al. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis. 2016;22:1664-6. DOI:10.3201/eid2209.160033
34. Alataby H, Atemnkeng F, Bains SS, et al. A COVID-19 case complicated by Candida dubliniensis and Klebsiella pneumoniae-carbapenem-resistant Enterobacteriaceae. J Med Cases. 2020;1:403-6. DOI:10.14740/jmc3588
35. Ceccarelli G, Borrazzo C, Pinacchio C, et al. Oral bacteriotherapy in patients with COVID-19: A retrospective cohort study. Front Nutr. 2020;7:613928. DOI:10.3389/fnut.2020.613928
36. d’Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the management of SARS-CoV2 Infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med. 2020;7:389. DOI:10.3389/fmed.2020.00389
37. Son SJ, Koh JH, Park MR, et al. Effect of the Lactobacillus rhamnosus strain GG and tagatose as a synbiotic combination in a dextran sulfate sodium-induced colitis murine model. J Dairy Sci. 2019;102:2844-53. DOI:10.3168/jds.2018-15013
38. Fuhren J, Schwalbe M, Rösch C, et al. Dietary inulin increases Lactiplantibacillus plantarum strain Lp900 persistence in rats depending on the dietary-calcium level. Appl Environ Microbiol. 2021;87:e00122-21. DOI:10.1128/AEM.00122-21
39. Shinde T, Vemuri R, Shastri S, et al. Modulating the Microbiome and Immune Responses Using Whole Plant Fibre in Synbiotic Combination with Fibre-Digesting Probiotic Attenuates Chronic Colonic Inflammation in Spontaneous Colitic Mice Model of IBD. Nutrients. 2020;12:2380. DOI:10.3390/nu12082380
40. Stadlbauer V, Horvath A, Komarova I, et al. Dysbiosis in early sepsis can be modulated by a multispecies probiotic: A randomised controlled pilot trial. Benef Microbes. 2019;10:265-78. DOI:10.3920/BM2018.0067
41. Moser AM, Spindelboeck W, Halwachs B, et al. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome. Eur J Nutr. 2019;58:2767-78. DOI:10.1007/s00394-018-1826-7
42. Chen J, Vitetta LJ. Modulation of Gut Microbiota for the Prevention and Treatment of COVID-19. Clin Med. 2021;10(13):2903. DOI:10.3390/jcm10132903
43. Archer DL, Kramer DC. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection. Front Med. 2020;7:292. DOI:10.3389/fmed.2020.00292
44. Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8:351-8. DOI:10.1080/19490976.2017.1284732
45. Chen J, Hall S, Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021;31(5):1-13. DOI:10.1002/rmv.2211
46. Luu M, Weigand K, Wedi F, et al. Regulation of the effector function of CD8(+) T cells by gut microbiota-derived metabolite butyrate. Sci Rep. 2018;8:14430. DOI:10.1002/rmv.2211
47. Takahashi Y, Hayakawa A, Sano R, et al. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19. Sci Rep. 2021;11:3379. DOI:10.1038/s41598-021-82970-2
48. Chemudupati M, Kenney AD, Smith AC, et al. Butyrate Reprograms Expression of Specific Interferon-Stimulated Genes. J Virol. 2020;94(16):e00326-20. DOI:10.1128/JVI.00326-20
49. Гриневич В.Б., Кравчук Ю.А., Педь В.И., и др. Ведение пациентов с заболеваниями органов пищеварения в период пандемии COVID-19. Клинические рекомендации Научного общества гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2020;179(7):4-51 [Grinevich VB, Kravchuk YuA, Ped VI, et al. Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2020;179(7):4-51 (in Russian)]. DOI:10.31146/1682-8658-ecg-179-7-4-51
50. Бахарев С.Д., Бауло Е.В., Быкова С.В., и др. COVID-19 и тонкая кишка. Терапевтический архив. 2021;93(3):343-7 [Bakharev SD, Baulo EV, Bykova SV, et al. COVID-19 and the small intestine. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(3):343-7 (in Russian)]. DOI:10.26442/00403660.2021.03.20066
________________________________________________
2. Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. DOI:10.3389/fimmu.2020.01446
3. Camilleri M, Lyle BJ, Madsen KL, et al. Role for diet in normal gut barrier function: developing guidance within the framework of food-labeling regulations. Am J Physiol Gastrointest Liver Physiol. 2019;317:G17-39. DOI:10.1152/ajpgi.00063.2019
4. Conte L, Toraldo DM. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170. DOI:10.1177/1753466620937170
5. Polevaya YeV, Vakhitov TYa, Sitkin SI. Enterosorbtion properties of psyllium (Mucofalk®) and its probable mechanisms at intestinal infections. Klinicheskie perspektivy gastroenterologii, gepatologii. 2011;2:35-9 (in Russian).
6. Ardatskaya MD, Butorova LI, Kalashnikova MA, et al. Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(8):923-31 (in Russian). DOI:10.26442/00403660.2021.08.201020
7. Tikhonova YeP, Kuzmina TYu, Minoranskaya YeI, Minoranskaya NS. The practical issues of application of Mucofalk® in Salmonella infection. Klinicheskie perspektivy gastroenterologii, gepatologii. 2011;4:36-9 (in Russian).
8. Iddir M, Brito A, Dingeo G, et al. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. Nutrients. 2020;12(6):1562. DOI:10.3390/nu12061562
9. Trompette A, Gollwitzer ES, Pattaroni C, et al. Dietary Fiber Confers Protection against Flu by Shaping Ly6c(-) Patrolling Monocyte Hematopoiesis and CD8(+) T Cell Metabolism. Immunity. 2018;48:992-1005. DOI:10.1016/j.immuni.2018.04.022
10. Alameddine J, Godefroy E, Papargyris L, et al. Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. Front Immunol. 2019;10:143. DOI:10.3389/fimmu.2019.00143
11. Zuo T, Liu Q, Zhang F, et al. Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Microbiome. 2021;9(1):91.
DOI:10.1186/s40168-021-01008-x
12. Benus RF, van der Werf TS, Welling GW, et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr. 2010;104:693-700. DOI:10.1017/S0007114510001030
13. Barbieri N, Herrera M, Salva S, et al. Lactobacillus rhamnosus CRL1505 nasal administration improves recovery of T-cell mediated immunity against pneumococcal infection in malnourished mice. Benef Microbes. 2017;8:393-405. DOI:10.3920/BM2016.0152
14. Laursen RP, Hojsak I. Probiotics for respiratory tract infections in children attending day care centers a systematic review. Eur J Pediatr. 2018;177:979-94.
DOI:10.1007/s00431-018-3167-1
15. Xia Y, Cao J, Wang M, et al. Effects of Lactococcus lactis subsp. lactis JCM5805 on colonization dynamics of gut microbiota and regulation of immunity in early ontogenetic stages of tilapia. Fish Shellfish Immunol. 2019;86:53-63. DOI:10.1016/j.fsi.2018.11.022
16. Yasui H, Kiyoshima J, Hori T, et al. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol. 1999;6:186-92. DOI:10.1128/CDLI.6.2.186-192.1999
17. Su M, Jia Y, Li Y, et al. Probiotics for the prevention of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. Respir Care. 2020;65:673-85. DOI:10.4187/respcare.07097
18. Zhang Q, Yue S, Wang W, et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Am J Chin Med. 2021;49(4):785-803. DOI:10.1142/S0192415X21500373
19. Han SK, Shin YJ, Lee DY, et al. Lactobacillus rhamnosus HDB1258 modulates gut microbiota-mediated immune response in mice with or without lipopolysaccharide-induced systemic inflammation. BMC Microbiol. 2021;21:146. DOI:10.1186/s12866-021-02192-4
20. Al Kassaa I, Hober D, Hamze M, et al. Antiviral potential of lactic acid bacteria and their bacteriocins. Probiotics Antimicrob Proteins. 2014;6:177-85. DOI:10.1007/s12602-014-9162-6
21. Baindara P, Chakraborty R, Holliday ZM, et al. Oral probiotics in coronavirus disease 2019: Connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials. New Microbes New Infect. 2021;40:100837.
22. Starosila D, Rybalko S, Varbanetz L, et al. Anti-influenza activity of a Bacillus subtilis probiotic strain. Antimicrob Agents Chemother. 2017;61:e00539-17. DOI:10.1128/AAC.00539-17
23. Zeng J, Wang CT, Zhang FS, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: A randomized controlled multicenter trial. Intensive Care Med. 2016;42:1018-28. DOI:10.1007/s00134-016-4303-x
24. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: A blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182:1058-64. DOI:10.1164/rccm.200912-1853OC
25. Jung YJ, Lee YT, Ngo VL, et al. Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection. Sci Rep. 2017;7:17360. DOI:10.1038/s41598-017-17487-8
26. Bidossi A, De Grandi R, Toscano M, et al. Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract. BMC Infect Dis. 2018;18:653. DOI:10.1186/s12879-018-3576-9
27. Di Pierro F. A possible probiotic (S. salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2. Minerva Med. 2020;111:281-3. DOI:10.23736/S0026-4806.20.06570-2
28. Bottari B, Castellone V, Neviani E. Probiotics and COVID-19. Int J Food Sci Nutr. 2021;72:293-9. DOI:10.1080/09637486.2020.1807475
29. Kumar R, Seo BJ, Mun MR, et al. Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens. Trop Anim Health Prod. 2010;42:1855-60. DOI:10.1007/s11250-010-9648-5
30. Chai W, Burwinkel M, Wang Z, et al. Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol. 2013;158:799-807. DOI:10.1007/s00705-012-1543-0
31. Liu YS, Liu Q, Jiang YL, et al. Surface-displayed porcine IFN-lambda3 in Lactobacillus plantarum inhibits porcine enteric coronavirus infection of porcine intestinal epithelial cells. J Microbiol Biotechnol. 2020;30:515-25. DOI:10.4014/jmb.1909.09041
32. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. 2020;5(7):644-5. DOI:10.1016/S2468-1253(20)30122-9
33. Esaiassen E, Cavanagh P, Hjerde E, et al. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis. 2016;22:1664-6. DOI:10.3201/eid2209.160033
34. Alataby H, Atemnkeng F, Bains SS, et al. A COVID-19 case complicated by Candida dubliniensis and Klebsiella pneumoniae-carbapenem-resistant Enterobacteriaceae. J Med Cases. 2020;1:403-6. DOI:10.14740/jmc3588
35. Ceccarelli G, Borrazzo C, Pinacchio C, et al. Oral bacteriotherapy in patients with COVID-19: A retrospective cohort study. Front Nutr. 2020;7:613928. DOI:10.3389/fnut.2020.613928
36. d’Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the management of SARS-CoV2 Infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med. 2020;7:389. DOI:10.3389/fmed.2020.00389
37. Son SJ, Koh JH, Park MR, et al. Effect of the Lactobacillus rhamnosus strain GG and tagatose as a synbiotic combination in a dextran sulfate sodium-induced colitis murine model. J Dairy Sci. 2019;102:2844-53. DOI:10.3168/jds.2018-15013
38. Fuhren J, Schwalbe M, Rösch C, et al. Dietary inulin increases Lactiplantibacillus plantarum strain Lp900 persistence in rats depending on the dietary-calcium level. Appl Environ Microbiol. 2021;87:e00122-21. DOI:10.1128/AEM.00122-21
39. Shinde T, Vemuri R, Shastri S, et al. Modulating the Microbiome and Immune Responses Using Whole Plant Fibre in Synbiotic Combination with Fibre-Digesting Probiotic Attenuates Chronic Colonic Inflammation in Spontaneous Colitic Mice Model of IBD. Nutrients. 2020;12:2380. DOI:10.3390/nu12082380
40. Stadlbauer V, Horvath A, Komarova I, et al. Dysbiosis in early sepsis can be modulated by a multispecies probiotic: A randomised controlled pilot trial. Benef Microbes. 2019;10:265-78. DOI:10.3920/BM2018.0067
41. Moser AM, Spindelboeck W, Halwachs B, et al. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome. Eur J Nutr. 2019;58:2767-78. DOI:10.1007/s00394-018-1826-7
42. Chen J, Vitetta LJ. Modulation of Gut Microbiota for the Prevention and Treatment of COVID-19. Clin Med. 2021;10(13):2903. DOI:10.3390/jcm10132903
43. Archer DL, Kramer DC. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection. Front Med. 2020;7:292. DOI:10.3389/fmed.2020.00292
44. Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8:351-8. DOI:10.1080/19490976.2017.1284732
45. Chen J, Hall S, Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021;31(5):1-13. DOI:10.1002/rmv.2211
46. Luu M, Weigand K, Wedi F, et al. Regulation of the effector function of CD8(+) T cells by gut microbiota-derived metabolite butyrate. Sci Rep. 2018;8:14430. DOI:10.1002/rmv.2211
47. Takahashi Y, Hayakawa A, Sano R, et al. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19. Sci Rep. 2021;11:3379. DOI:10.1038/s41598-021-82970-2
48. Chemudupati M, Kenney AD, Smith AC, et al. Butyrate Reprograms Expression of Specific Interferon-Stimulated Genes. J Virol. 2020;94(16):e00326-20. DOI:10.1128/JVI.00326-20
49. Grinevich VB, Kravchuk YuA, Ped VI, et al. Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2020;179(7):4-51 (in Russian). DOI:10.31146/1682-8658-ecg-179-7-4-51
50. Bakharev SD, Baulo EV, Bykova SV, et al. COVID-19 and the small intestine. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(3):343-7 (in Russian). DOI:10.26442/00403660.2021.03.20066
Авторы
В.А. Ахмедов*
ФГБОУ ВО «Омский государственный медицинский университет», Омск, Россия
*v_akhmedov@mail.ru
Omsk State Medical University, Omsk, Russia
*v_akhmedov@mail.ru
ФГБОУ ВО «Омский государственный медицинский университет», Омск, Россия
*v_akhmedov@mail.ru
________________________________________________
Omsk State Medical University, Omsk, Russia
*v_akhmedov@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.